New Edge Advisors, LLC Lantern Pharma Inc. Transaction History

New Edge Advisors, LLC

$11.2 Billion
Q1 2024

A detailed history of New Edge Advisors, LLC transactions in Lantern Pharma Inc. stock. As of the latest transaction made, New Edge Advisors, LLC holds 160,532 shares of LTRN stock, worth $974,429. This represents 0.01% of its overall portfolio holdings.

Number of Shares

160,532

Previous 165,972 3.28%

Holding current value

$974,429

Previous $710,000 98.87%

% of portfolio

0.01%

Previous 0.01%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$3.73 - $10.65 $20,291 - $57,936	-5,440 Reduced 3.28%	160,532 $1.41 Million
Q4 2023 Feb 13, 2024	SELL	$2.48 - $4.39 $10,066 - $17,819	-4,059 Reduced 2.39%	165,972 $710,000
Q3 2023 Nov 14, 2023	SELL	$3.41 - $5.51 $4,889 - $7,901	-1,434 Reduced 0.84%	170,031 $579,000
Q2 2023 Aug 14, 2023	SELL	$4.56 - $6.02 $2,963 - $3,912	-650 Reduced 0.38%	171,465 $967,000
Q1 2023 May 12, 2023	SELL	$4.3 - $6.2 $3,108 - $4,482	-723 Reduced 0.42%	172,115 $831,000

Q4 2022 Feb 14, 2023	BUY	$4.29 - $6.04 $7,803 - $10,986	1,819 Added 1.06%	172,838 $1.04 Million
Q3 2022 Nov 14, 2022	BUY	$4.74 - $6.5 $4,962 - $6,805	1,047 Added 0.62%	171,019 $817,000
Q2 2022 Aug 09, 2022	BUY	$4.82 - $7.45 $968 - $1,497	201 Added 0.12%	169,972 $971,000
Q1 2022 May 13, 2022	BUY	$5.6 - $8.22 $14,923 - $21,906	2,665 Added 1.59%	169,771 $1.21 Million
Q4 2021 Feb 17, 2022	BUY	$7.11 - $11.04 $79,966 - $124,166	11,247 Added 7.22%	167,106 $1.33 Million
Q3 2021 Oct 29, 2021	BUY	$10.53 - $14.93 $47,837 - $67,826	4,543 Added 3.0%	155,859 $1.74 Million
Q2 2021 Jul 22, 2021	BUY	$12.94 - $19.89 $1.96 Million - $3.01 Million	151,316 New	151,316 $2.21 Million

Others Institutions Holding LTRN

# of Institutions

Shares Held

1.07M

Call Options Held

124K

Put Options Held

22.2K

View Full List

About Lantern Pharma Inc.

Ticker LTRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 10,830,900
Market Cap $65.7M
Description
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-30...

More about LTRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of New Edge Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on New Edge Advisors, LLC with notifications on news.

Account

New Edge Advisors, LLC Lantern Pharma Inc. Transaction History